
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LABORATORY INDUSTRY REPORT
NATIONAL LAB REPORTER
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.